High-dose therapy with autologous peripheral blood stem cell (PBSC) support is a therapeutic procedure frequently used in patients with indolent and mantle-cell nonHodgkin's lymphomas (NHL). 1, 2 Purging the autografts by means of positive selection methods using anti-CD34 antibodies have been used to reduce the risk of relapse after transplantation, 3, 4 although they have been associated with an increased rate of infectious complications. We report an unusually high rate of immune complications in patients receiving a CD34-selected autograft.
From January 1996 to December 2000, 20 patients with follicular and mantle-cell NHL not achieving a complete remission with first-line chemotherapy or with sensitive relapsed disease were candidates for transplantation using CD34-selected autografts. Nine out of 20 (45%) with adequate mobilization received a purged inoculum, while the rest received unmanipulated grafts. CD34 þ selection was performed using the Baxter 300 Isolex System (Baxter, Irvine, CA, USA) and the Cellpro Ceprate System (Cellpro, Seattle, WA, USA), according to the manufacturer's specifications. Preparative regimens used were cyclophosphamide (Cy) and total-body irradiation (TBI) and escalated CBV. Supported care consisted of fluconazol 200 mg/day. No prophylactic antibiotics or intravenous immunoglobulins were administered routinely during transplantation. No growth factors were administered unless engraftment had not occurred by day þ 25. Haemoglobin was maintained at a level of 8 g/dl and platelet counts over 20 Â 10 9 /l. All transfusion products were in-line filtered and irradiated with 30 Gy. Trymethoprim-sulfametoxazole or inhaled pentamidine was administered after engraftment. Blood cultures were performed when patients had 4381C of temperature and broadspectrum antibiotic treatment was started. Patients with pneumonia were evaluated by bronchoalveolar lavage (BAL) and/or lung biopsy, and tested for bacterial, fungal, mycoplasma, legionella, nocardia, cytomegalovirus (CMV) and other viral cultures. CMV antigenemia was not routinely performed. Herpes simplex virus (HSV) infections were clinically diagnosed; varicella-zoster virus (VZV) infections were diagnosed by typical dermatomal skin lesions or viral culture.
The median number of TNC/kg and CD34 þ cells/kg were 8.18 Â 10 8 /kg (range 4.76-14.83) and 3.04 Â 10 6 /kg (range 1.1-10.52), respectively. The median time for neutrophil and platelet engraftments were 12 (range 9-35) and 25 days (range 10-48), respectively. One patient with graft failure on day þ 25 was successfully reconstituted with unmanipulated backup cells. No related-mortality post transplant was observed at 100 days. With a median follow-up of surviving patients of 3.94 years (range 1.38-7.43 years), seven of nine patients died, five due to lymphoma and two in remission due to late toxicities: progressive multifocal leukoencephalopathy (PML) and secondary leukemia, at 14 months and 33 months post transplant, respectively.
The overall incidence of viral infections was 77.78%, mainly related to HSV infections type I (66.67%). None developed CMV disease. Other non-herpes viral infections observed were: a PML by JC virus on day þ 317 and an infection in the genital area by human papilloma virus (HPV), 3 years after transplantation.
Three of nine of the patients (33%) developed unexpected severe immune complications. The first patient developed on day þ 28 burn-like skin lesions spread all over the trunk and limbs diagnostic of pemphigus vulgaris after skin biopsy with direct immunofluorescence study. The second patient required admission to a critical care unit on day þ 65 for ventilatory support due to a GuillainBarre syndrome. Both were successfully treated with steroids. The third patient developed two immune disorders: on day þ 62 a leukocytoclastic vasculitis in both legs, with evolution into ulcers that resolved with oral steroids, and on day þ 135 the patient noted shortness of breath and respiratory symptoms. A high-resolution thoracic CT scan was suggestive of bronchiolytis obliterans, confirmed by transbronchial biopsy. The patient required long-lasting steroid treatment and although bronchiolytis evolved with success, he died 9 months later because of PML due to JC virus, unresponsive to treatment with cidofovir. 5 All patients were in remission when these complications were diagnosed.
Although controversial, CD34 þ selected transplants have been associated with an increased risk for viral infections during the first period post transplant when compared with unmanipulated ones. The removal of T and NK cells, essential in the reconstitution of the immune system, have been implicated as the underlying mechanism, as previously reported. 6, 7 Divine et al 8 and Bomberger et al 9 reported a delayed reconstitution of the immune system up to 12 months for both CD4 þ and CD8 þ subsets in lymphoma patients following an autologous CD34-selected PBSC transplant. However, we have not found reports regarding immune events in patients receiving CD34-selected grafts with the exception of Carreras et al, 10 who reported a case of uveitis in one of 15 patients with multiple sclerosis. Our observations are intriguing considering that no immune complications were diagnosed during the same period among the patients who received unmanipulated transplants.
We conclude that: (1) Although it is feasible, positive selection could not be done in many patients because of the insufficient target numbers of CD34 þ cells. (2) Recipients of CD34-selected autologous PBSC are at high risk of developing severe immune disorders and viral infections. (3) Because of severe complications, other purging procedures should be evaluated such as in vivo purging with anti-CD20, which shows evidence of clearance of residual tumor cells in recent studies.
